PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes ...

The biotech is putting Voxzogo, its drug for skeletal disorders, at the center of plans to grow revenue the rest of this decade and beyond.

The funding comes amid a slowdown in venture investment for gene and cell therapy startups, and will support development of multiple solid tumor programs.

The Phase 2 results for Recursion’s cerebral cavernous malformation treatment are the first in a series of important trial readouts for the high-profile “techbio” company.

BALTIMORE, MD, September 3, 2024 — Sapio Sciences, the science-awareTM lab informatics platform, today announced significant ...

Pharma companies can thrive in 2024 by leveraging digital intelligence to anticipate trends, analyze sentiment, and engage audiences. Discover how data-driven insights drive success.

Tolebrutinib, which Sanofi acquired in a $3.7 billion deal, failed two studies in people with relapsing disease, but succeeded in a type of multiple sclerosis that has no approved therapies.

While results from two after-the-fact analyses were “reassuring,” outside experts urged “continued vigilance” to ensure GLP-1 drugs don’t worsen problems in people with preexisting mental health ...

Detailed results from the Helios-B study support summary findings disclosed in June. But they may not make vutrisiran the standard of care as easily as Alnylam hopes.

Under a collaboration with NextRNA Therapeutics, Bayer will access the biotech’s platform to target long, non-coding RNA interactions with small molecule drugs.

Far fewer venture funding rounds were closed by cell and gene therapy developers over the first six months of 2024 than in prior years. Experts say there are several factors.

Despite “positive” results, shares of the biotech slid by 20%. Analysts cautioned that Neurocrine shouldn’t get “the benefit of the doubt” with its data.